Adjuvant Global Health Technology Fund, L.P. - Nov 14, 2023 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
10%+ Owner
Signature
Adjuvant Global Health Technology Fund, L.P., By: Adjuvant Capital GP, L.P., its sole general partner, By: Adjuvant Capital Management, L.L.C., its sole general partner, By: Kabeer Aziz, Secretary, /s/ Kabeer Aziz
Stock symbol
ANTX
Transactions as of
Nov 14, 2023
Transactions value $
-$29,224
Form type
4
Date filed
11/16/2023, 06:59 PM
Previous filing
Oct 3, 2023
Next filing
Jan 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Sale -$24.6K -1.52K -0.07% $16.15 2.08M Nov 14, 2023 Direct F1, F2, F3
transaction ANTX Common Stock Sale -$4.65K -288 -0.07% $16.15 393K Nov 14, 2023 By Adjuvant Global Health Technology Fund DE, L.P. F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.285, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.
F4 Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. Kabeer Aziz, a member of the Issuer's board of directors, is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities.